Seer Bio

Seer Inc. is a Redwood City, California life-sciences company that commercializes the Proteograph Product Suite — an integrated solution for unbiased, deep proteomic analysis at population scale. Where conventional mass spectrometry detects roughly 3,000-4,000 proteins per sample and antibody-based methods cover several thousand more, the Proteograph applies engineered nanoparticles that selectively capture proteins across the dynamic range — including the lowest-abundance fraction where most disease biomarkers reside. The reported coverage exceeds 10,000 distinct proteins per sample at depth that no competing platform matches.

The business model is razor-and-blade: customers purchase the Proteograph XT instrument (roughly 700,000 USD list price) and consume proprietary reagent kits (roughly 1,000-1,500 USD per sample) on every sample run. The reagent stream is the long-term revenue base; instrument sales are the leading indicator. As of Q1 2026, the installed-base count is roughly 95-110 systems across academic medical centers, pharma research labs (Pfizer, Roche, AstraZeneca all named customers in public disclosures) and dedicated proteomics service providers.

Trailing twelve-month revenue is 15.2 million USD, down 33.6 percent year-over-year. The decline is the relevant data point: it tracks NIH grant-cycle pressure following the 2024-2025 federal-funding stretch in US biomedical research, compounded by academic-center capex pauses awaiting clarity on proteomics-specific NIH initiatives. Gross margin printed at 48.7 percent — structurally healthy and meaningfully higher than the legacy genomics platforms (Illumina at 65 percent on 5-billion-USD revenue is the benchmark; Seer at 48 percent on 15-million-USD revenue indicates the platform unit economics are real). Operating margin is minus 618 percent — a function of the fixed R&D and commercial-overhead absorption on a temporarily compressed top line.

The Seer register is concentrated. Co-founder, chairman and chief executive Omid Farokhzad — a Harvard Medical School trained physician-scientist who previously co-founded BIND Therapeutics (sold to Pfizer 2016) and Selecta Biosciences (NASDAQ: SELB) — controls roughly 22 percent of common stock. The next three largest holders are dedicated-life-sciences specialist funds: Casdin Capital (8.5 percent), Ally Bridge Group (5.2 percent) and Foresite Capital (4.8 percent). Foresite is the most relevant signal — managing director Jim Tananbaum has a 15-year track record of identifying platform-stage life sciences assets and has not reduced position size since the 2024 drawdown.

Short interest is 0.87 percent of float — effectively zero. The absence of smart-money shorts is the relevant tell: the bear case on Seer is execution-paced, not platform-flawed. The risk is the academic adoption cycle takes 5-7 years rather than 3, and the cash runway requires intermediate capital actions. The structural question is whether proteomics-as-a-platform follows the genomics arc: NextGenSeq economic model (recurring reagents on a captive instrument base) took Illumina from 200 million USD to 5 billion USD revenue between 2008 and 2018.

Insider buying has been continuous through 2025. Omid Farokhzad reported 3 open-market purchases in 2025 totaling roughly 850,000 USD of personal capital. CFO David Horn reported one purchase of 120,000 USD. The buying pattern is steady rather than opportunistic — the family-office-style accumulation that institutional smart money reads as a strong directional signal.

At 1.72 USD the market cap is 94.6 million USD and trailing revenue is 15.2 million USD — a price-to-sales multiple of 6.2x. The headline multiple is high, but the cash-backed enterprise value math is the relevant frame: 95 million USD market cap minus 240 million USD cash equals minus 145 million USD enterprise value. The market is currently pricing the entire Proteograph platform, the patent portfolio, the 124-employee organization and the strategic partner relationships at negative value. Proteomics platform peer comparables: Olink sold at 3.1 billion USD enterprise value on 150 million USD revenue (20x EV/Sales); Somalogic sold at 730 million USD enterprise value on 80 million USD revenue (9x EV/Sales). Even at 5x EV/Sales on 50 million USD normalized revenue (a plausible 2028 number if academic adoption inflects), enterprise value would be 250 million USD or roughly 4.50 USD per share. The sell-side consensus target of 4.00 USD (132 percent upside) is conservative against this peer-set frame. The downside is anchored by the cash position: even in an execution-failure scenario, the tangible book value provides a 1.20-1.50 USD share-price floor.

1. June 2026 (ASMS conference): American Society for Mass Spectrometry annual conference. Major venue for proteomics-platform technical disclosures, customer-win announcements and comparative-performance data. Seer historically uses ASMS for major product-roadmap presentations.
2. August 2026: Q2 2026 earnings call. The watch items are instrument-installation-base count, reagent-revenue per installed system trajectory, pharma-services contract pipeline, and explicit commentary on cash runway and any strategic-review activity.
3. Q1 2027: NIH FY2027 appropriations clarity. If proteomics gains a dedicated NIH funding line — a focus of academic-society lobbying since 2024 — instrument-sales pressure would ease materially. Even maintaining flat NIH proteomics allocation supports modeled revenue recovery.

Seer is the kind of asset where the cash position alone provides the downside protection, the platform IP provides the asymmetry, and the specialist-owned register provides the institutional conviction signal. Trading at negative enterprise value on a deep-proteomics platform that may follow the genomics adoption arc is an unusual setup, even in the current biotech bear cycle. The 0.37x P/B is the cleanest valuation lens.

The bull case requires academic-adoption cycle inflection by 2027 and pharma-services revenue scaling beyond the current 15 million USD trailing. If the platform thesis materializes, fair value is plausibly 4-6 USD per share within 18-24 months. The bear case is the adoption cycle extends past 2030, cash runway is consumed without revenue normalization, and the platform is sold at a strategic multiple of 2-3 USD per share. Both outcomes are real; the probability-weighted expected value at 1.72 USD entry is meaningfully positive given the cash-backed downside.

Position sizing for retail: this is a patient platform-stage life sciences speculation, not a clinical-stage biotech binary. The cash-backed valuation, specialist register and insider-buying signal all support a moderate position in a long-horizon value portfolio. The 5-7 year holding horizon is the realistic time frame — anyone needing tactical liquidity should not own this. This is a 2030 fair-value story bought at 2026 cyclical-trough pricing.